Why the study?
Uncertainty persists regarding the true efficacy, optimal timing, duration, regimen, and bleeding risk of dual antiplatelet therapy for secondary prevention after TIA or non-cardioembolic ischemic stroke.
Does dual antiplatelet therapy reduce recurrent stroke compared to single antiplatelet therapy in adults with non-cardioembolic transient ischemic attack or ischemic stroke?
Comparison
Dual antiplatelet therapy vs single antiplatelet therapy
Design
Systematic review and meta-analysis of randomized trials and cohort studies
Authors
Loading...
DAPT was associated with lower recurrent stroke; leaves open optimal duration, regimen, and bleeding trade-offs before changing practice.
Does dual antiplatelet therapy reduce recurrent stroke compared to single antiplatelet therapy in adults with non-cardioembolic transient ischemic attack or ischemic stroke?
Early, time-limited dual antiplatelet therapy with a loading dose significantly reduces recurrent stroke risk after non-cardioembolic TIA or mild-to-moderate ischemic stroke, with a modest increase in major bleeding.
Hlupeni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: